Evidence map›Paper›PMID 37671283›Full record

ArticleFrontiers in reproductive health2023

Development of

Maria Friberg, Kara Woeller, Vighter Iberi, Paolo Palacio Mancheno, James Riedeman, Lisa Bohman, Catherine C Davis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in reproductive health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Maria Friberg *Baby, Feminine and Family Care Microbiology, The Procter & Gamble Company, Mason, OH, United States.
Kara Woeller *Baby, Feminine and Family Care, Global Product Stewardship, The Procter & Gamble Company, Cincinnati, OH, United States.
Vighter IberiCorporate Functions Analytical, The Procter & Gamble Company, Mason, OH, United States.
Paolo Palacio ManchenoCorporate Functions Analytical, The Procter & Gamble Company, Mason, OH, United States.
James RiedemanBaby, Family and Feminine Care Analytical Chemistry, The Procter & Gamble Company, Cincinnati, OH, United States.
Lisa BohmanData Modeling and Sciences, The Procter & Gamble Company, Mason, OH, United States.
Catherine C Davis *Department of Medical Microbiology and Immunology, School of Medicine, Creighton University, Omaha, NE, United States.
Procter & Gamble (United States) · USCreighton University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Menstrual cups (MC) are a reusable feminine hygiene product. A recent publication suggested that Methods: MCs were incubated anaerobically for 12 h in Vaginal Defined Media (VDM) with the two morphologically distinct bacteria, Results: Samples collected from the media control had expected growth of both organisms after 12 h of incubation. Samples collected from VDM broth were similar to media control at the end of the 12-h study. Total Discussion: The data support continued safe use of the Tampax® cup when used and maintained as recommended.

Indexed as

biofilm formationcleaning instructionsmenstrual cupsafetystaphylococcal toxic shock syndrome

Identifiers

PMID37671283
PMCPMC10475951
OpenAlexW4386033597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.